Business Context and Reporting Period
Onconetix, Inc. (formerly Blue Water Biotech, Inc.) filed this Form 8-K for events occurring on December 15, 2023. On that date, Onconetix completed the acquisition of Proteomedix AG, a Swiss biotechnology company, through a share exchange. Proteomedix became a direct, wholly owned subsidiary of Onconetix.
Transaction and Key Financial Terms
- Onconetix issued 4,083,779 shares of common stock, representing approximately 19.9% of Onconetix’s outstanding common stock at closing.
- Onconetix also issued 2,692,633 shares of Series B Convertible Preferred Stock, each convertible into 100 common shares, or an aggregate of 269,263,300 common shares, subject to stockholder approval and other conditions.
- The stated aggregate value of the exchange consideration was approximately $75 million, less the value attributable to certain Proteomedix stock options and subject to indemnification adjustments.
- Approximately $7.5 million of the exchange consideration was issued to affiliates of Tungsten Advisors as compensation for advisory services.
- Following conversion of the preferred stock and completion of the related investment, the parties anticipated that Proteomedix sellers would own approximately 79.8% of Onconetix, the investor approximately 5.9%, and pre-closing Onconetix stockholders approximately 5.4%.
- Onconetix entered into a subscription agreement for a proposed $5.0 million private placement of units priced at $0.25 per unit. Each unit consists of one common share and a pre-funded warrant exercisable for 0.3 common shares at $0.001 per share.
- The proposed subscription financing was expected to close after stockholder approval of the preferred-stock conversion issuance. The filing states that additional investor shares may be issuable if the common stock VWAP during the 270 days following closing is below the $0.25 purchase price.
Material Changes Versus the Prior Comparable Period
- The filing reflects a significant change in corporate structure and ownership through the acquisition of Proteomedix.
- The company changed its name from Blue Water Biotech, Inc. to Onconetix, Inc.
- Christian Brühlmann was appointed Chief Strategy Officer and Ralph Schiess was appointed Chief Science Officer, each effective December 15, 2023.
- The company’s post-stockholder-approval board is expected to comprise five directors, with three designated by Proteomedix and two designated by Onconetix.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing does not provide revenue, net income, cash flow, margin, debt, cash balance, liquidity, or operating guidance for the reporting period.
- Conversion of the Series B Preferred Stock requires stockholder approval and an increase in Onconetix’s authorized common shares. If approval is not obtained by January 1, 2025, eligible holders may require cash settlement based on the market value of the underlying common shares.
- The potential cash-settlement obligation could create a material liquidity requirement; the filing does not quantify the resulting liability.
- Onconetix agreed to prepare a proxy statement and a Form S-1 or Form S-4 registration statement covering the securities issued or issuable in the transaction.
- The transaction may require review or approval by CFIUS and a Nasdaq change-of-control application. The parties agreed to pursue required approvals and respond to regulatory inquiries.
- Indemnification claims may be asserted until the earlier of stockholder approval or June 30, 2024, with additional seller indemnification obligations continuing through the first anniversary of closing. Certain indemnification payments are limited to recourse against exchange and conversion shares.
- The exchange and conversion shares are subject to lock-up restrictions generally ending six months after stockholder approval, subject to exceptions.
- Certain Proteomedix executives entered into three-year non-competition and non-solicitation agreements.
- Onconetix may undertake permitted debt or equity financings of up to $25 million between closing and conversion.
Most Important Facts for Investors to Verify
- Whether Onconetix obtained stockholder approval for the conversion shares and authorized-share increase.
- Whether the $5.0 million subscription financing closed and the final number of shares and warrants issued.
- The ultimate dilution and ownership percentages after preferred-stock conversion, financing, option adjustments, and any indemnification adjustments.
- Any cash-settlement obligation arising from failure to complete the conversion by the applicable deadline.
- Proteomedix’s historical and prospective revenue, profitability, cash requirements, debt, and operating performance, which are not provided in this Form 8-K text.
- The status of CFIUS review, Nasdaq change-of-control requirements, and related regulatory conditions.
- The transaction’s final accounting treatment, including purchase price allocation, goodwill, intangible assets, and any material fair-value adjustments.